Sorrento Therape

Company Profile

Sorrento Therape had its IPO on 2010-01-11 under the ticker symbol SRNE.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Sorrento Therape has a staff strength of 799 employees.

Stock update

Shares of Sorrento Therape opened at $0.31 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.3 - $0.34, and closed at $0.33.

This is a +8.92% increase from the previous day's closing price.

A total volume of 1,403,499 shares were traded at the close of the day’s session.

In the last one week, shares of Sorrento Therape have slipped by -2.29%.

Sorrento Therape's Key Ratios

Sorrento Therape has a market cap of $168.36 million, indicating a price to book ratio of 4.0084 and a price to sales ratio of 8.2922.

In the last 12-months Sorrento Therape’s revenue was $60.32 million with a gross profit of $-167049000 and an EBITDA of $-390896000. The EBITDA ratio measures Sorrento Therape's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Sorrento Therape’s operating margin was -669.17% while its return on assets stood at -36.87% with a return of equity of -378.92%.

In Q4, Sorrento Therape’s quarterly earnings growth was a positive 0% while revenue growth was a positive 44.3%.

Sorrento Therape’s PE and PEG Ratio

Forward PE

1.1046

Trailing PE

0

PEG

-0.07

Its diluted EPS in the last 12-months stands at $-1.527 per share while it has a forward price to earnings multiple of 1.1046 and a PEG multiple of -0.07. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sorrento Therape’s profitability.

Sorrento Therape stock is trading at a EV to sales ratio of 9.5963 and a EV to EBITDA ratio of -1.1411. Its price to sales ratio in the trailing 12-months stood at 8.2922.

Sorrento Therape stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$460.06 million

Total Liabilities

$165.63 million

Operating Cash Flow

$1.68 million

Capital Expenditure

$86000

Dividend Payout Ratio

0%

Sorrento Therape ended 2024 with $460.06 million in total assets and $0 in total liabilities. Its intangible assets were valued at $460.06 million while shareholder equity stood at $-125498000.00.

Sorrento Therape ended 2024 with $1.82 million in deferred long-term liabilities, $165.63 million in other current liabilities, 55000.00 in common stock, $-2099063000.00 in retained earnings and $80.27 million in goodwill. Its cash balance stood at $37.66 million and cash and short-term investments were $37.66 million. The company’s total short-term debt was $63,685,000 while long-term debt stood at $21.40 million.

Sorrento Therape’s total current assets stands at $100.76 million while long-term investments were $0 and short-term investments were $12.66 million. Its net receivables were $26.52 million compared to accounts payable of $14.59 million and inventory worth $11.31 million.

In 2024, Sorrento Therape's operating cash flow was $1.68 million while its capital expenditure stood at $86000.

Comparatively, Sorrento Therape paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.33

52-Week High

$2.16

52-Week Low

$0.161

Analyst Target Price

$7.67

Sorrento Therape stock is currently trading at $0.33 per share. It touched a 52-week high of $2.16 and a 52-week low of $2.16. Analysts tracking the stock have a 12-month average target price of $7.67.

Its 50-day moving average was $0.33 and 200-day moving average was $1.3 The short ratio stood at 4.96 indicating a short percent outstanding of 0%.

Around 131.4% of the company’s stock are held by insiders while 4280.6% are held by institutions.